Jefferies Group's NKTR Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 38,165 shares of Nektar Therapeutics (NKTR) worth $2.66 M, representing 0.02% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 4 quarters.
Based on 13F filings, Jefferies Group has maintained this position in NKTR for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 38,165 shares. Largest reduction occurred in Q4 2025, reducing 191,300 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Nektar Therapeutics (NKTR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Nektar Therapeutics (NKTR) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +38,165 | New Buy | 38,165 | $69.81 |
| Q1 2026 | -111,900 | Sold Out | 0 | $0.00 |
| Q4 2025 | -191,300 | Reduce 63.09% | 111,900 | $42.28 |
| Q3 2025 | +303,200 | New Buy | 303,200 | $56.90 |
Jefferies Group's Nektar Therapeutics Investment FAQs
Jefferies Group first purchased Nektar Therapeutics (NKTR) in Q3 2025, acquiring 303,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Nektar Therapeutics (NKTR) for 4 quarters since Q3 2025.
Jefferies Group's largest addition to Nektar Therapeutics (NKTR) was in Q3 2025, adding 303,200 shares worth $17.25 M.
According to the latest 13F filing for Q2 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 38,165 shares of Nektar Therapeutics (NKTR), valued at approximately $2.66 M.
As of the Q2 2026 filing, Nektar Therapeutics (NKTR) represents approximately 0.02% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Nektar Therapeutics (NKTR) was 303,200 shares, as reported at the end of Q3 2025.